Passage Bio Stock Plunges as FDA Demands Full Randomized Trial for PBFT02
Passage Bio fell after the FDA demanded a larger trial; the drug shows promise for brain disease, but its future is now costlier and slower.
/ 2 items
Passage Bio fell after the FDA demanded a larger trial; the drug shows promise for brain disease, but its future is now costlier and slower.
Oppenheimer just started coverage on Passage Bio with an Outperform rating and $30 price target. They call the recent pullback a buying opportunity ahead of key PBFT02 data in H1 2026.